Literature DB >> 26899768

Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation.

Sofia Cuenca1, Maria J Ruiz-Cano2, Juan Ramón Gimeno-Blanes3, Alfonso Jurado2, Clara Salas4, Iria Gomez-Diaz5, Laura Padron-Barthe6, Jose Javier Grillo7, Carlos Vilches8, Javier Segovia1, Domingo Pascual-Figal3, Enrique Lara-Pezzi6, Lorenzo Monserrat5, Luis Alonso-Pulpon1, Pablo Garcia-Pavia9.   

Abstract

BACKGROUND: Dilated cardiomyopathy (DCM) is the most frequent cause of heart transplantation (HTx). The genetic basis of DCM among patients undergoing HTx has been poorly characterized. We sought to determine the genetic basis of familial DCM HTx and to establish the yield of modern next generation sequencing (NGS) technologies in this setting.
METHODS: Fifty-two heart-transplanted patients due to familial DCM underwent NGS genetic evaluation with a panel of 126 genes related to cardiac conditions (59 associated with DCM). Genetic variants were initially classified as pathogenic mutations or as variants of uncertain significance (VUS). Final pathogenicity status was determined by familial cosegregation studies.
RESULTS: Initially, 24 pathogenic mutations were found in 21 patients (40%); 25 patients (48%) carried 19 VUS and 6 (12%) did not show any genetic variant. Familial evaluation of 220 relatives from 36 of the 46 families with genetic variants confirmed pathogenicity in 14 patients and allowed reclassification of VUS as pathogenic in 17 patients, and as non-pathogenic in 3 cases. At the end of the study, the DCM-causing mutation was identified in 38 patients (73%) and 5 patients (10%) harbored only VUS. No genetic variants were identified in 9 cases (17%).
CONCLUSIONS: The genetic spectrum of familial DCM patients undergoing HTx is heterogeneous and involves multiple genes. NGS technology plus detailed familial studies allow identification of causative mutations in the vast majority of familial DCM cases. Detailed familial studies remain critical to determine the pathogenicity of underlying genetic defects in a substantial number of cases.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  familial dilated cardiomyopathy; genetics; heart transplantation; mutation; next generation sequencing

Mesh:

Year:  2016        PMID: 26899768     DOI: 10.1016/j.healun.2015.12.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  19 in total

1.  Mutational and phenotypic spectra of KCNE1 deficiency in Jervell and Lange-Nielsen Syndrome and Romano-Ward Syndrome.

Authors:  Rabia Faridi; Risa Tona; Alessandra Brofferio; Michael Hoa; Rafal Olszewski; Isabelle Schrauwen; Muhammad Z K Assir; Akhtar A Bandesha; Asma A Khan; Atteeq U Rehman; Carmen Brewer; Wasim Ahmed; Suzanne M Leal; Sheikh Riazuddin; Steven E Boyden; Thomas B Friedman
Journal:  Hum Mutat       Date:  2018-12-12       Impact factor: 4.878

2.  Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations.

Authors:  Fernando Domínguez; Sofía Cuenca; Zofia Bilińska; Rocío Toro; Eric Villard; Roberto Barriales-Villa; Juan Pablo Ochoa; Folkert Asselbergs; Arjan Sammani; Maria Franaszczyk; Mohammed Akhtar; Maria José Coronado-Albi; Diego Rangel-Sousa; Jose F Rodriguez-Palomares; Juan Jiménez-Jáimez; José Manuel Garcia-Pinilla; Tomás Ripoll-Vera; Maria Victoria Mogollón-Jiménez; Ana Fontalba-Romero; Dolores Garcia-Medina; Julian Palomino-Doza; David de Gonzalo-Calvo; Marcos Cicerchia; Joel Salazar-Mendiguchia; Clara Salas; Sabine Pankuweit; Thomas Morris Hey; Jens Mogensen; Paul J Barton; Philippe Charron; Perry Elliott; Pablo Garcia-Pavia
Journal:  J Am Coll Cardiol       Date:  2018-11-13       Impact factor: 24.094

Review 3.  Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data.

Authors:  M Alejandra Restrepo-Cordoba; Oscar Campuzano; Tomás Ripoll-Vera; Marta Cobo-Marcos; Irene Mademont-Soler; José M Gámez; Fernando Dominguez; Esther Gonzalez-Lopez; Laura Padron-Barthe; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Ramon Brugada; Pablo Garcia-Pavia
Journal:  J Cardiovasc Transl Res       Date:  2017-01-30       Impact factor: 4.132

4.  Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy.

Authors:  Rocío Toro; Sara Blasco-Turrión; Francisco José Morales-Ponce; Pablo Gonzalez; Pablo Martínez-Camblor; Amador López-Granados; Ramon Brugada; Oscar Campuzano; Alexandra Pérez-Serra; Felix Rosa Longobardo; Alipio Mangas; Vicenta Llorente-Cortes; David de Gonzalo-Calvo
Journal:  J Mol Med (Berl)       Date:  2018-07-14       Impact factor: 4.599

5.  High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation.

Authors:  Baerbel Klauke; Anna Gaertner-Rommel; Uwe Schulz; Astrid Kassner; Edzard Zu Knyphausen; Thorsten Laser; Deniz Kececioglu; Lech Paluszkiewicz; Ute Blanz; Eugen Sandica; Antoon J van den Bogaerdt; J Peter van Tintelen; Jan Gummert; Hendrik Milting
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

Review 6.  Potential new mechanisms of pro-arrhythmia in arrhythmogenic cardiomyopathy: focus on calcium sensitive pathways.

Authors:  C J M van Opbergen; M Delmar; T A B van Veen
Journal:  Neth Heart J       Date:  2017-03       Impact factor: 2.380

Review 7.  Importance of Genetic Testing in Dilated Cardiomyopathy: Applications and Challenges in Clinical Practice.

Authors:  Arsonval Lamounier Júnior; Filipe Ferrari; Renato Max; Luiz Eduardo Fonteles Ritt; Ricardo Stein
Journal:  Arq Bras Cardiol       Date:  2019-09-02       Impact factor: 2.000

8.  Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy.

Authors:  Pablo Garcia-Pavia; Yuri Kim; Maria Alejandra Restrepo-Cordoba; Ida G Lunde; Hiroko Wakimoto; Amanda M Smith; Christopher N Toepfer; Kelly Getz; Joshua Gorham; Parth Patel; Kaoru Ito; Jonathan A Willcox; Zoltan Arany; Jian Li; Anjali T Owens; Risha Govind; Beatriz Nuñez; Erica Mazaika; Antoni Bayes-Genis; Roddy Walsh; Brian Finkelman; Josep Lupon; Nicola Whiffin; Isabel Serrano; William Midwinter; Alicja Wilk; Alfredo Bardaji; Nathan Ingold; Rachel Buchan; Upasana Tayal; Domingo A Pascual-Figal; Antonio de Marvao; Mian Ahmad; Jose Manuel Garcia-Pinilla; Antonis Pantazis; Fernando Dominguez; A John Baksi; Declan P O'Regan; Stuart D Rosen; Sanjay K Prasad; Enrique Lara-Pezzi; Mariano Provencio; Alexander R Lyon; Luis Alonso-Pulpon; Stuart A Cook; Steven R DePalma; Paul J R Barton; Richard Aplenc; Jonathan G Seidman; Bonnie Ky; James S Ware; Christine E Seidman
Journal:  Circulation       Date:  2019-04-16       Impact factor: 29.690

9.  Molecular analysis of inherited cardiomyopathy using next generation semiconductor sequencing technologies.

Authors:  Chaoxia Lu; Wei Wu; Fang Liu; Kunqi Yang; Jiacheng Li; Yaping Liu; Rongrong Wang; Nuo Si; Peng Gao; Yongtai Liu; Shuyang Zhang; Xue Zhang
Journal:  J Transl Med       Date:  2018-08-30       Impact factor: 5.531

10.  A mutation update for the FLNC gene in myopathies and cardiomyopathies.

Authors:  Job A J Verdonschot; Els K Vanhoutte; Godelieve R F Claes; Apollonia T J M Helderman-van den Enden; Janneke G J Hoeijmakers; Debby M E I Hellebrekers; Amber de Haan; Imke Christiaans; Ronald H Lekanne Deprez; Hanne M Boen; Emeline M van Craenenbroeck; Bart L Loeys; Yvonne M Hoedemaekers; Carlo Marcelis; Marlies Kempers; Esther Brusse; Jaap I van Waning; Annette F Baas; Dennis Dooijes; Folkert W Asselbergs; Daniela Q C M Barge-Schaapveld; Pieter Koopman; Arthur van den Wijngaard; Stephane R B Heymans; Ingrid P C Krapels; Han G Brunner
Journal:  Hum Mutat       Date:  2020-03-20       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.